THERAPEUTIC STRATEGIES
The
treatment of patients with inflammation involves two pri-mary goals: first, the
relief of symptoms and the maintenance of function, which are usually the major
continuing complaints of the patient; and second, the slowing or arrest of the
tissue-damaging process. In rheumatoid arthritis, response to therapy can be
quantitated using several measures such as the Disease Activity Scale (DAS),
the Clinical Disease Activity Index (CDAI), and the American College of
Rheumatology Response index (ACR Response). The first two are continuous
variables denoting both state and change, while the latter is solely a change
measure. In the latter, the scoring values of ACR20, ACR50, and ACR70 denote
the percentage of patients showing an improvement of 20%, 50%, or 70%,
respectively, in a global assessment of signs and symptoms.
Reduction
of inflammation with nonsteroidal
anti-inflammatory drugs (NSAIDs) often results in relief of pain
forsignificant periods. Furthermore, most of the nonopioid analgesics (aspirin,
etc) have anti-inflammatory effects, so they are appropri-ate for the treatment
of both acute and chronic inflammatory conditions.The glucocorticoids also have powerful anti-inflammatory effects and
when first introduced were considered to be the ulti-mate answer to the
treatment of inflammatory arthritis. Although there are data that low-dose
corticosteroids have disease-modifying properties, their toxicity makes them
less favored than other medications, when it is possible to use the others.
However, the glucocorticoids continue to have a significant role in the
long-term treatment of arthritis.
Another
important group of agents is characterized as disease-modifying antirheumatic drugs (DMARDs) and biologics (asubset of the DMARDs).
They decrease inflammation, improve symptoms, and slow the bone damage
associated with rheuma-toid arthritis. They affect more basic inflammatory
mechanisms than do glucocorticoids or the NSAIDs. They may also be more toxic
than those alternative medications.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.